Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

15.20 +0.76 (+5.26%)
Streaming Delayed Price Updated: 12:34 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corp

< Previous 1 2 3 4 5 6 7 8 Next >
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biomerica (NASDAQ:BMRA) stock inc... 
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing... 
Via Benzinga
Analyst Ratings For Prothena Corp
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the follo... 
Via Benzinga
Expert Ratings For Prothena Corp
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Rises To 7% In December
Following the market opening Wednesday, the Dow traded up 0.56% to 36,453.49 while the NASDAQ rose 0.79% to 15,273.08. The S&P also rose, gaining, 0.60% to 4,741.45. The U.S.... 
Via Benzinga
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
The list features stocks from diverse sectors as the economy recovers from the pandemic. 
Via Investor's Business Daily
Expert Ratings For Prothena Corp
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA 
Via Benzinga
Expert Ratings For Prothena Corp
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA 
Via Benzinga
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Exposures COVID-19
7 A-Rated Biotechs to Buy for the Long Run
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples. 
Via InvestorPlace
Prothena Corp: Q3 Earnings Insights
Prothena Corp (NASDAQ:PRTA) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
7 A-Rated Healthcare Stocks to Buy for the Long Haul
It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. 
Via InvestorPlace
Expert Ratings For Prothena Corp
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the foll... 
Via Benzinga
What 9 Analyst Ratings Have To Say About Prothena Corp
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA 
Via Benzinga
Where Prothena Corp Stands With Analysts
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has ... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Where Prothena Corp Stands With Analysts
Prothena Corp (NASDAQ:PRTA) has observed the following an... 
Via Benzinga
What 8 Analyst Ratings Have To Say About Prothena Corp
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA 
Via Benzinga
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
Promising drug candidates could lead to a best-in-class Alzheimer's treatment. 
Via The Motley Fool
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
Return on Capital Employed Insights for Prothena Corp
According to Benzinga Pro, during Q2, Prothena Corp (NASDAQ:PRTA) earned $27.95 million, a 187.04% increase from the preceding quarter. Prothena Corp also posted a total of $60.07... 
Via Benzinga
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Jefferies raised the price target on Tesla, Inc. (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Recap: Prothena Corp Q2 Earnings
Shares of Prothena Corp (NASDAQ:PRTA) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 187.88% year over year to $0... 
Via Benzinga
Why Is Novo Nordisk Buying a Rare-Disease Candidate?
The company is mainly known for its diabetes drugs but has some background in rare-disease drugs. 
Via The Motley Fool
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.